Date: 2014-05-23
Type of information: Licensing agreement
Compound: antibody engineering technologies
Company: Chugai Pharmaceuticals (Japan) Roche (Switzerland)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On May 23, 2014, Chugai Pharmaceutical announced that it has entered into a licensing agreement with Roche regarding Chugai’s proprietary innovative antibody engineering technologies. Under this license agreement, Chugai grants Roche a license to utilize its antibody engineering technologies and Roche is able to generate innovative antibodies applying this proprietary technologies for Roche’s candidates. Roche may also request Chugai to create antibodies for targets that Roche selects. With this license agreement, Roche comes to be able to develop antibody drugs which aim for first-in-class or best-in-class utilizing Chugai’s proprietary innovative antibody engineering technologies. In particular, by using these proprietary technologies, it is expected for Roche to have wider choices to select antigens and to achieve therapeutic effects that were not possible by conventional technologies. Target antibody technologies for this license agreement - SMART-Ig (Sequential Monoclonal Antibody Recycling Technology): Technology for creating Recycling antibody which extends the activity of antibody by enabling a single antibody bind to the antigen multiple times. The development compound applying this technology is SA237 (expected indication: neuromyelitis optica (NMO)) - SMART-Fc (Sequential Monoclonal Antibody Recycling Technology - Fc domain): Technology for creating Sweeping antibody which enables eliminating pathogenetic antigen from plasma - ART-Ig (Asymmetric Re-engineering Technology - Immunoglobulin): Technology for facilitating manufacturing of bispecific antibody. The development compound applying this technology is ACE 910 (Hemophilia A). - ART-Fc (Asymmetric Re-engineering Technology - Fc domain): ADCC enhancing technology applying ART-Ig. The technology is applicable for oncology drug creation. - TwoB-Ig (Fc?RIIB selective binding technology - Immunoglobulin): Fc engineering technology to selectively enhance inhibitory Fc?RIIB binding. The technology is applicable for autoimmune disease drug creation. - ACT-Ig ( Antibody Charge engineering Technology - Immunoglobulin): this technology enables to extend half life of antibody. The development compounds applying this technology are SA237 (expected indication: neuromyelitis optica (NMO)), ACE 910 (Hemophilia A), CIM331 (Atopic dermatitis).
Financial terms: Under the license agreement, Chugai will receive an upfront fee, annual usage fee, milestone and royalty payments from Roche.
Latest news:
